Emyria Ltd (ASX:EMD) MD Michael Winlo tells Proactive the company has expanded its proprietary cannabinoid medicine pipeline, with the launch of a high potency, highly bioavailable Ultra-Pure CBD dose form called EMD-RX9, targeting prescription-based registrations. The launch follows the company’s recent commercialisation success of its low-dose CBD capsule, EMD-RX5 with Aspen Pharmacare (JSE:APN) in Australia.
Contact DetailsProactive Investors
Jonathan Jackson
+61 413 713 744
